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ABSTRACT
Objective To derive, and externally validate, a risk score 
for cardiovascular death among patients with type 2 
diabetes and newly diagnosed diabetic nephropathy (DN).
Research design and methods Two independent 
prospective cohorts with type 2 diabetes were used to 
develop and externally validate the risk score. The derivation 
cohort comprised 2282 patients with an incident, clinical 
diagnosis of DN. The validation cohort includes 950 patients 
with incident, biopsy- proven diagnosis of DN. The outcome 
was cardiovascular death within 2 years of the diagnosis 
of DN. Logistic regression was applied to derive the risk 
score for cardiovascular death from the derivation cohort, 
which was externally validated in the validation cohort. The 
score was also estimated by applying the United Kingdom 
Prospective Diabetes Study (UKPDS) risk score in the external 
validation cohort.
Results The 2- year cardiovascular mortality was 12.05% 
and 11.79% in the derivation cohort and validation cohort, 
respectively. Traditional predictors including age, gender, 
body mass index, blood pressures, glucose, lipid profiles 
alongside novel laboratory test items covering five test 
panels (liver function, serum electrolytes, thyroid function, 
blood coagulation and blood count) were included in the final 
model.
C- statistics was 0.736 (95% CI 0.731 to 0.740) and 0.747 
(95% CI 0.737 to 0.756) in the derivation cohort and 
validation cohort, respectively. The calibration slope was 
0.993 (95% CI 0.974 to 1.013) and 1.000 (95% CI 0.981 
to 1.020) in the derivation cohort and validation cohort, 
respectively.
The UKPDS risk score substantially underestimated 
cardiovascular mortality.
Conclusions A new risk score based on routine 
clinical measurements that quantified individual risk 
of cardiovascular death was developed and externally 
validated. Compared with the UKPDS risk score, which 
underestimated the cardiovascular disease risk, the new 
score is a more specific tool for patients with type 2 
diabetes and DN. The score could work as a tool to identify 
individuals at the highest risk of cardiovascular death 
among those with DN.
BaCkgROund
Diabetic nephropathy (DN) is one of the most 
significant complications of diabetes mellitus 
and the most frequent cause of end- stage 
renal disease.1 Cardiovascular complications, 
induced by accelerating arteriosclerosis, 
comprise nearly 50% of all comorbidity and 
mortality in patients with type 2 diabetes 
and those with renal insufficiency caused by 
Significance of this study
What is already known about this subject?
 ► Cardiovascular disease has been found to be the 
primary cause of death in people with diabetic ne-
phropathy (DN).
 ► No risk scores had been developed and external-
ly validated to predict short- term cardiovascular 
mortality in cohorts for patients with DN and type 
2 diabetes.
What are the new findings?
 ► Using two independent prospective cohorts, a new 
risk score to predict cardiovascular death within 2 
years since the diagnosis of DN was developed and 
externally validated with good discrimination and 
calibration.
 ► Unlike the new score, the UKPDS score substantially 
underestimated cardiovascular mortality.
How might these results change the focus of 
research or clinical practice?
 ► The score is derived based on routine clinical mea-
surements that are commonly available for patients 
with DN either in an outpatient setting or in the in-
patient setting.
 ► The score could work as a screening tool to identi-
fy individuals at the highest risk of cardiovascular 
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diabetes have a yet greater risk of cardiovascular compli-
cations.2 To reduce future cardiovascular mortality risk 
among patients with DN, risk algorithms predicting 
future individual absolute risk of cardiovascular mortality 
are required to help clinicians and patients to assess the 
management status and develop personalised care strate-
gies.3 In previous studies, a number of prognostic factors 
have been identified including microalbuminuria,4 hypo-
thyroidism,5 osteopontin6 and the metabolic syndrome.7 
However, few studies have calculated risk algorithms to 
identify those with DN, and those who are at particularly 
high risk of cardiovascular mortality, especially short- 
term cardiovascular mortality.
The aim of the present study was to develop and vali-
date a multivariable risk algorithm to predict cardiovas-
cular deaths within 2 years of diagnosis of type 2 DN 
among patients with type 2 diabetes.
MeTHOds
data source and study population
We used two independent prospective cohorts from the 
First Affiliated Hospital of Zhengzhou University, Henan, 
China: one (derivation) based on the electronic health 
record data from outpatient and inpatient registries 
to develop our cardiovascular mortality risk score and 
another (validation) based on biopsy registry cohort data 
for external validation. The diagnosis of type 2 diabetes 
was based on the American Diabetes Association criteria.8
deRivaTiOn COHORT
A total 2282 patients in the derivation cohort were 
enrolled through the outpatient and inpatient depart-
ments (except Department of Nephrology) in the First 
Affiliated Hospital of Zhengzhou University. This is the 
largest hospital in China and provides both primary and 
secondary care to Henan province residents. To develop 
a risk score that could potentially be applied to the 
general DN population, all patients with incident (based 
on patients’ previous medical records) DN clinically 
diagnosed in the hospital between 1 January 2015 and 31 
December 2016 were enrolled as the derivation cohort. 
Each patient’s clinical diagnosis date was recorded as the 
enrol date (baseline examination date). DN was defined 
as the presence of nephropathy in patients with type 2 
diabetes and albuminuria >300 mg/g creatinine; or 
patients with diabetes and albuminuria >30–300 mg/g 
creatinine and an estimated glomerular filtration rate 
(eGFR) <60 mL/min/1.73 m2.9
external validation cohort
The study included 950 patients with type 2 diabetes with 
biopsy- proven DN newly diagnosed between 1 January 
2015 and 31 December 2016. Each patient’s biopsy- 
proven diagnosis date was recorded as the enroll date 
(baseline examination date). Patients were either outpa-
tients or inpatients under the Department of Nephrology, 
the First Affiliated Hospital of Zhengzhou University. The 
diagnosis of DN was made based on histological charac-
teristics, including glomerular hypertrophy, thickened 
capillary basement membranes, diffuse mesangial expan-
sion (sclerosis), nodular mesangial sclerosis, exudative 
lesions such as capsular drop or fibrin cap, mesangiolysis, 
mescapillary microaneurysm or hyalinosis of afferent and 
efferent arterioles, using appropriate standards for renal 
biopsy including light microscopy, electron microscopy 
and immunofluorescence examination.10 Patients with 
other glomerular disease concomitant with DN were 
excluded from this study. Renal biopsy was performed 
for precise diagnosis of renal lesions with the consent of 
each patient. The biopsy results were reviewed by three 
clinicians and the diagnosis was made only based on the 
agreement of more than two clinicians.
defining cardiovascular death
Every patient included in both the derivation cohort 
and the validation cohort were followed up for 2 years 
following the baseline examination, for example, the 
follow- up time would be 5 January 2017 if the baseline 
examination was 6 January 2015. We defined the primary 
outcome as death with cardiovascular disease as the 
primary diagnosis over the 2- year follow- up. An outcome 
assessment committee at the First Affiliated Hospital 
of Zhengzhou University reviewed medical history and 
death certificates and determined the final underlying 
cause of death. Two clinicians in the committee inde-
pendently verified the diagnosis, and discrepancies were 
adjudicated by discussion involving additional committee 
members. All clinicians in the committee were unaware 
of patient’s baseline status.
Candidate predictors, missing data and power calculations
Two demographic characteristics (age and gender), three 
clinical measurements (body mass index (BMI), systolic 
blood pressure (SBP) and diastolic blood pressure 
(DBP)) and six glucose and lipid profiles measurements 
(fasting glucose, hemoglobin A1c (HbA1c), total choles-
terol, high- density lipoprotein (HDL) cholesterol, low- 
density lipoprotein (LDL) cholesterol, triglyceride) and 
62 laboratory test items (covering full blood count, liver 
function and blood coagulation tests, serum electrolytes 
and renal function) routinely measured among patients 
with incident type 2 DN in both outpatient clinics and 
inpatient departments were initially identified. To mini-
mize overfitting of the model and maintain the proper 
statistical power, all 62 laboratory test items were inde-
pendently reviewed and combined into 16 integrated 
predictors (online supplementary table 1) based on the 
clinical utilization by two clinicians at the First Affiliated 
Hospital of Zhengzhou University. Discrepancies were 
adjudicated by discussion involving an additional clini-
cian. In total, 27 potential predictors were selected for 
the subsequent model development.
Our derivation cohort had missing information on 
BMI (26.2%), SBP (27.4%), DBP (27.2%), fasting 
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Table 1 Baseline characteristics of study cohorts





Cardiovascular deaths, n (%) Outcome 275 (12.05%) 112 (11.79%)
Age, years General 59.00 (50.00 to 67.00) 56.50 (48.00 to 62.00)
Male gender, n (%) General 1350 (59.15%) 535 (56.32%)
Systolic blood pressure, mm Hg General 150.00 (135.00 to 167.00) 156.00 (140.00 to 171.00)
Diastolic blood pressure, mm 
Hg
General 89.00 (80.00 to 97.00) 82.00 (52.00 to 96.00)
Body mass index, kg/m2 General 26.00 (20.35 to 32.15) 26.00 (19.39 to 28.48)
Direct bilirubin, µmol/L Liver function 3.40 (2.30 to 5.10) 2.35 (1.50 to 3.10)
Cholinesterase, U/L Liver function 6.85 (4.70 to 9.25) 6.77 (3.40 to 9.13)
Pre- albumin, mg/dL Liver function 234.04 (185.33 to 282.00) 246.27 (193.90 to 284.20)
Total bile acid, µmol/L Liver function 3.90 (1.85 to 7.68) 3.30 (1.90 to 7.62)
Albumin, g/L Liver function 39.60 (32.20 to 60.83) 36.60 (25.40 to 43.26)
Alkaline phosphatase, IU/L Liver function 74.00 (60.00 to 93.00) 81.75 (65.13 to 94.75)
Alanine transaminase, U/L Liver function 16.00 (11.00 to 24.00) 12.00 (9.00 to 21.75)
Gamma- glutamyl transferase, 
U/L
Liver function 23.00 (15.00 to 39.50) 18.00 (12.25 to 34.88)
Globulin, g/L Liver function 25.48 (22.40 to 29.10) 25.25 (21.11 to 30.88)
Indirect bilirubin, µmol/L Liver function 3.70 (2.40 to 5.70) 2.40 (1.69 to 4.10)
Total bilirubin, µmol/L Liver function 7.20 (4.90 to 10.75) 4.83 (3.45 to 7.13)
Total protein, g/dL Liver function 63.40 (57.50 to 68.10) 61.64 (53.20 to 65.98)
Aspartate transaminase, U/L Liver function 17.00 (13.00 to 22.67) 14.42 (11.00 to 18.00)
24 hours total urine protein, g Renal function 2.80 (0.09 to 3.57) 3.38 (1.49 to 5.67)
24 hours total urine amount, L Renal function 2.00 (1.00 to 3.50) 3.26 (1.50 to 33.87)
Urine microalbumin, 
mg/L/24 hours
Renal function 149.07 (18.00 to 940.00) 179.27 (35.00 to 958.00)
pH of urine sample Renal function 6.00 (5.75 to 6.45) 6.00 (5.70 to 6.50)
Urine- specific gravity Renal function 1.01 (1.00 to 1.02) 1.01 (1.00 to 1.02)
Urine total protein, mg/24 hours Renal function 421.10 (43.00 to 2078.86) 467.30 (255.25 to 3225.92)
Creatinine, μmoI/L Renal function 86.00 (62.00 to 200.00) 117.25 (68.50 to 417.25)
Urine acid, µmol/L Renal function 303.00 (241.00 to 378.00) 326.00 (265.00 to 383.00)
Estimated glomerular filtration 
rate, mL/min/1.73 m2
Renal function 35.79 (14.35 to 53.42) 32.13 (12.63 to 46.38)
Urea, mmol/L Renal function 7.38 (5.35 to 12.62) 9.73 (5.59 to 18.37)
Magnesium, mmol/L Serum electrolytes 0.93 (0.86 to 1.01) 0.96 (0.87 to 1.04)
HCO3, mEq/L Serum electrolytes 23.60 (21.30 to 25.90) 22.50 (19.35 to 25.70)
Calcium, mmol/L Serum electrolytes 2.23 (2.11 to 2.31) 2.13 (2.05 to 2.27)
Chlorine, mmol/L Serum electrolytes 102.30 (99.80 to 105.20) 102.00 (99.00 to 107.33)
Potassium, mmol/L Serum electrolytes 4.36 (4.01 to 4.70) 4.53 (4.29 to 4.90)
Sodium, mmol/L Serum electrolytes 141.00 (138.50 to 143.10) 140.33 (137.00 to 143.00)
Phosphorus, mmol/L Serum electrolytes 1.23 (1.07 to 1.40) 1.33 (1.16 to 1.47)
Free triiodothyronine, pmol/L Thyroid function 4.24 (3.63 to 4.88) 4.13 (3.36 to 4.50)
Free thyroxine, pmol/L Thyroid function 11.93 (10.23 to 13.90) 11.43 (9.25 to 14.39)
Thyroid- stimulating hormone, 
µIU/mL
Thyroid function 2.04 (1.12 to 3.86) 2.83 (1.17 to 4.96)
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Prothrombin time Blood coagulation 9.80 (9.10 to 10.70) 9.70 (8.90 to 10.60)
Prothrombin time activity Blood coagulation 128.00 (110.00 to 147.15) 126.68 (112.00 to 151.00)
Activated partial thromboplastin 
time, s
Blood coagulation 33.56 (30.10 to 37.00) 32.40 (29.80 to 35.60)
Fibrinogen, g/L Blood coagulation 3.19 (2.61 to 3.96) 3.22 (2.84 to 3.87)
Thrombin time, s Blood coagulation 14.80 (13.60 to 16.50) 15.65 (13.80 to 17.30)
International normalized ratio Blood coagulation 0.86 (0.81 to 0.94) 0.87 (0.80 to 0.93)
Basophil, 109/L Blood count 0.03 (0.02 to 0.04) 0.03 (0.02 to 0.04)
Basophil, % Blood count 0.50 (0.40 to 0.65) 0.53 (0.40 to 0.60)
Eosinophil granulocyte, 109/L Blood count 0.13 (0.08 to 0.20) 0.15 (0.09 to 0.24)
Eosinophil granulocyte, % Blood count 2.00 (1.20 to 3.00) 2.20 (1.08 to 3.90)
Hematocrit, % Blood count 0.37 (0.31 to 0.44) 0.31 (0.28 to 0.39)
Hemoglobin, g/L Blood count 117.00 (96.00 to 135.00) 98.33 (89.13 to 123.96)
Lymphocyte, 109/L Blood count 1.70 (1.25 to 2.10) 1.39 (1.21 to 2.13)
Lymphocyte, % Blood count 26.10 (19.38 to 33.10) 25.80 (17.50 to 32.10)
Mean corpuscular hemoglobin, 
pg
Blood count 29.90 (28.90 to 31.00) 29.65 (27.40 to 30.80)
Mean corpuscular hemoglobin 
concentration, g/L
Blood count 329.00 (323.00 to 334.00) 324.25 (320.25 to 332.88)
Mean corpuscular volume, fL Blood count 91.00 (87.80 to 93.80) 90.00 (84.80 to 93.20)
Monocytes, 109/L Blood count 0.50 (0.40 to 0.63) 0.43 (0.36 to 0.57)
Monocytes, % Blood count 7.50 (6.33 to 8.90) 7.65 (6.00 to 8.68)
Mean platelet volume, fL Blood count 8.50 (7.80 to 9.30) 8.35 (7.54 to 8.98)
Neutrophil, 109/L Blood count 4.20 (3.20 to 5.50) 4.07 (3.30 to 4.93)
Neutrophil, % Blood count 63.00 (55.40 to 70.03) 64.83 (56.50 to 70.03)
Plateletcrit, % Blood count 0.17 (0.14 to 0.21) 0.18 (0.14 to 0.22)
Platelet distribution width, % Blood count 16.75 (16.40 to 17.15) 16.93 (16.50 to 17.39)
Platelets, 109/L Blood count 196.00 (160.00 to 239.00) 187.00 (157.50 to 247.00)
Red blood cell, 1012/L Blood count 4.29 (3.24 to 6.79) 3.57 (3.12 to 6.35)
Red blood cell distribution 
width, %
Blood count 13.60 (13.00 to 14.49) 13.83 (13.06 to 14.55)
White blood cell count, 109/L Blood count 6.55 (4.80 to 10.00) 6.38 (5.05 to 11.18)
Glucose, mmol/L Blood glucose/lipids 7.66 (5.50 to 10.63) 6.80 (5.14 to 10.12)
High- density lipoprotein 
cholesterol, mmol/L
Blood glucose/lipids 1.05 (0.86 to 1.30) 0.95 (0.81 to 1.34)
Hemoglobin A1c, mmol/mol Blood glucose/lipids 62.80 (49.70 to 80.30) 58.50 (53.0 to 84.70)
Low- density lipoprotein 
cholesterol, mmol/L
Blood glucose/lipids 2.62 (1.99 to 3.35) 2.97 (2.10 to 3.66)
Total cholesterol, mmol/L Blood glucose/lipids 4.28 (3.54 to 5.09) 4.70 (3.74 to 5.64)
Triglyceride, mmol/L Blood glucose/lipids 1.43 (1.02 to 2.19) 1.70 (1.00 to 2.28)
Table 1 Continued
hemoglobin (3.6%), mean platelet volume (3.6%), 
monocyte (3.6%), red blood cell distribution width 
(3.6%), magnesium (12.1%), sodium (12.1%), chlorine 
(12.1%), activated partial thromboplastin time (22.8%), 
D- dimer (12.8%), thrombin time (22.8%), fibrinogen 
(22.8%) and fibrinogen degradation products (22.8%) 
. We used multiple imputation to replace missing values 
by using a chained equation approach based on all candi-
date predictors and outcomes. We created 27 imputed 
datasets for missing variables that were then combined 
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Table 2 Final multivariate analysis for cardiovascular death risk among people with type 2 diabetes and a new clinical 
diagnosis of DN in derivation cohort
Parameters Coefficients 95% CI
Gender: male vs female 0.157086 0.113221 to 0.200952
(Age/10)3 0.000782 −0.002189 to 0.003752
(Age/10)3×ln(age/10) 0.000499 −0.000851 to 0.001849
(Body mass index/10)3 1.057959 0.938973 to 1.176945
(Body mass index/10)3×ln(body mass index/10) −0.831356 −0.923908 to−0.738804
Systolic blood pressure ≥150 mm Hg 0.132676 0.087332 to 0.178021
Diastolic blood pressure ≥90 mm Hg 0.022270 −0.022518 to 0.067057
(Fasting glucose/10)2 0.562659 0.480369 to 0.644950
(Fasting glucose/10)3 −0.207944 −0.246155 to −0.169732
(e(high- density lipoprotein cholesterol)/10)−0.5 −5.667237 −6.281152 to −5.053321
(e(high- density lipoprotein cholesterol)/10)−0.5×ln(e(high- density lipoprotein cholesterol)/10) −1.998909 −2.190463 to −1.807355
{e[log10(Triglyceride)]}−0.5 0.350930 −0.475933 to 1.177792
{e[log10(Triglyceride)]}−0.5×ln{e[log10(Triglyceride)]} −0.308807 −0.692824 to 0.075210
Low- density lipoprotein cholesterol ≥2.60 0.322825 0.278944 to 0.366706
International normalized ratio ≥0.86 or D- dimer ≥0.15 or fibrinogen ≥3.19 or 
thrombin time ≥14.8
1.929119 1.779267 to 2.078971
Prothrombin time activity ≥128 or activated partial thromboplastin time ≥33.56 or 
prothrombin time ≥9.8
1.005904 0.852349 to 1.159459
Thyroid- stimulating hormone ≥2.04 or free thyroxine ≥11.93 or free 
triiodothyronine ≥4.24
−0.176353 −0.234195 to −0.118511
Magnesium ≥0.93 or phosphorus ≥1.23 or potassium ≥4.36 or sodium ≥141 0.138010 0.061919 to 0.214101
HCO3 ≥23.6 or chlorine ≥102.3 or calcium ≥2.23 −0.545899 −0.601485 to −0.490313
Total bilirubin ≥7.2 or total protein ≥63.4 −0.741628 −0.790879 to −0.692376
Cholinesterase ≥6.85 or alanine transaminase ≥16 or gamma- glutamyl 
transtransferase ≥23 or alkaline phosphatase ≥74
−0.278849 −0.342571 to −0.215127
Direct bilirubin ≥3.4 or globulin ≥25.48 or indirect bilirubin ≥3.7 0.385626 0.324596 to 0.446655
Urine- specific gravity ≥1.01 or 24 hours total urine protein ≥0.86 or urea ≥7.38 1.789318 1.605494 to 1.973141
Basophil ≥0.03×109/L or eosinophil granulocyte ≥0.13×109/L or mean 
corpuscular hemoglobin ≥29.9 or platelet distribution width ≥16.75 or plateletcrit 
≥0.169% or monocytes ≥7.5%
−1.364007 −1.552228 to −1.175786
Lymphocyte ≥26.1% or neutrophil ≥63% or hemoglobin ≥117 −0.476919 −0.588630 to −0.365208
Hematocrit ≥0.37 or red blood cell distribution width ≥13.6% or neutrophil 
≥4.2×109/L or mean corpuscular hemoglobin concentration ≥329
−0.228664 −0.359169 to −0.098159
Lymphocyte ≥1.7×109/L or mean corpuscular volume ≥91 or monocytes×109/
L≥0.5
0.411002 0.346310 to 0.475694
Constant −4.073395 −5.295054 to −2.851736
DN, diabetic nephropathy.
Using the same method, we also imputed values for 
patients with missing information on BMI (16.2%), SBP 
(17.4%), DBP (22.2%), fasting glucose (22.1%), hemato-
crit (2.6%), mean corpuscular hemoglobin (2.6%), mean 
platelet volume (2.6%), monocyte (2.6%), red blood cell 
distribution width (12.7%), magnesium (12.5%), sodium 
(2.1%), chlorine (12.7%), activated partial thrombo-
plastin time (16.7%), D- dimer (16.7%), thrombin time 
(16.7%), fibrinogen (22.7%) and fibrinogen degrada-
tion products (16.7%) in the external validation cohort.
On the basis of 275 cardiovascular deaths and all 27 
potential predictors before backward elimination in our 
derivation cohort, we had an effective sample size of 10.2 
cardiovascular deaths per parameter, above the minimum 
requirement suggested by Peduzzi et al.12
ethical approval
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Figure 1 Assessing calibration in the derivation cohort (left) and the validation cohort (right) for cardiovascular death.
Table 3 Model diagnostics (with 95% CI)
Measure
Development
External validationApparent performance Test performance
Average 
optimism Optimism corrected
C- statistic 0.738 (0.733 to 0.742) 0.736 (0.726 to 0.746) +0.002 0.736 (0.731 to 0.740) 0.747 (0.737 to 0.756)
Calibration 
slope
1.000 (0.981 to 1.019) 0.993 (0.990 to 0.997) +0.007 0.993 (0.974 to 1.013) 1.000 (0.981 to 1.020)
statistical analysis for model derivation and external 
validation
We treated occurrence of cardiovascular deaths within 2 
years of the beginning of follow- up, as binary outcome 
measures. For each of the 27 potential predictors 
(covering 73 items as described above), we used a univari-
able logistic regression model to calculate the unadjusted 
ORs. For derivation of the risk prediction model, we 
initially included all candidate predictors in a multivari-
able logistic regression model. We tried to use both frac-
tional polynomial terms and binary terms (using medians 
of measurements in the derivation cohort as cut- offs) 
of continuous predictors (age, BMI, SBP, DBP, HbA1c, 
glucose, total cholesterol, HDL, LDL and triglyceride). 
The term with best model fit statistics (minimum Bayesian 
information criterion (BIC)) in the full model was used 
as the term for above- mentioned continuous predictors.
Through backward elimination, we excluded five 
predictors (covering 19 items) from the multivariate 
model as they were not statistically significant (p>0.1 
based on change in log likelihood).13 After elimination, 
we reinserted the excluded predictors into the final 
model to further check whether it became statistically 
significant. We also rechecked fractional polynomial 
terms at this stage and re- estimated them where neces-
sary. Finally, 27 parameters (binary or polynomial terms) 
from 22 predictors remained in the final model.
We formed risk equations for predicting the log odds 
of cardiovascular death by using the estimated regres-
sion coefficients multiplied by the corresponding 
predictors included in our model together with the inter-
cepts. This process ultimately led to equations for the 
predicted risk=1/(1+e−riskscore), where the ‘risk score’ is 
the predicted log odds of cardiovascular death from the 
developed model.
To facilitate model utilization in clinical practice, the 
logistic regression equations were transformed into prog-
nostic score charts. The coefficients in the logistic regres-
sion equation were multiplied by 12.5 and rounded to 
the nearest integer to obtain the prognostic score per 
predictor. Multiplication by 12.5 was chosen to place the 
majority of the coefficients close to an integer, thereby 
minimizing the effects of rounding. The sum of all prog-
nostic scores reflects patients’ probability of cardiovas-
cular deaths.14
We assessed the performance of the models in terms 
of the C- statistic and calibration slope (where 1.00 is 
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Figure 2 Assessing calibration in the validation cohort for cardiovascular death by applying the United Kingdom Prospective 
Diabetes Study (UKPDS) risk score.
any randomly selected pair of people with DN with and 
without outcomes, the patient with the outcome had 
a higher predicted risk.15 A value of o.50 indicated no 
discrimination and 1.00 represents perfect discrimina-
tion. We then undertook internal validation to correct 
measures of predictive performance for optimism (over-
fitting) by bootstrapping 100 samples of the derivation 
data. We repeated the model derivation process in each 
bootstrap sample to produce a model, applied the model 
to the same bootstrap sample to quantify apparent 
performance and applied the model to the original 
dataset to test model performance (calibration slope and 
C- statistic) and optimism (difference in the test perfor-
mance and apparent performance). We then estimated 
the overall optimism across all models.
We applied our risk prediction model to each patient 
with DN in the external validation cohort on the basis of 
the presence of one or more predictors. We examined 
the performance of this final model both in the deriva-
tion dataset and then in the external validation dataset 
in terms of discrimination by calculating the C- statistic. 
We examined calibration by plotting agreement between 
predicted and observed risks across tenth of the predicted 
risks.
We also applied the United Kingdom Prospective 
Diabetes Study (UKPDS) risk score16 in the external 
validation cohort to estimate the 2- year risk of cardiovas-
cular disease (CVD) in terms of model calibration, to test 
whether this general risk score for patients with type 2 
diabetes would still be suitable for patients with type 2 
diabetes and DN. As the smoking information was not 
accessible in this study, estimates were made assuming 
both the lowest (all non- smoking) and highest (all 
smoking) scenarios.
We used Stata V.15.0 for all statistical analyses. This 
study was conducted and reported in line with the Trans-
parent Reporting of a multivariate prediction model for 
Individual Prediction Diagnosis guidelines.17
ResulTs
study participants
In our derivation cohort, we analyzed information on 
2282 patients with DN with 275 cardiovascular deaths 
within 2 years. Our validation cohort had information 
on 950 patients with DN with 112 cardiovascular deaths. 
Table 1 summarizes the basic characteristics and poten-
tial predictors of the study population. For general char-
acteristics, patients in the derivation cohort had higher 
age, higher proportion of males and higher DBP and SBP 
compared with those in the validation cohort. Test items 
within the thyroid function test panel, blood coagulation 
test panel, full blood count test panel and lipid profile 
test panel were similar between the derivation cohort and 
the validation cohort. Most test items in the liver function 
test panel were generally higher among patients in the 
derivation cohort compared with those in the validation 
cohort, except for pre- albumin and alkaline phosphate 
which were lower in the derivation cohort; and cholines-
terase, albumin and globulin which were similar between 
the derivation cohort and the validation cohort. Most 
test items in the renal function test panel were generally 
lower in the derivation cohort compared with those in 
the derivation cohort, except for eGFR which was higher 
in the derivation cohort, and pH of the urine sample 
and urine- specific gravity which were similar between the 
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Figure 3 Practical prognostic score charts for predicting cardiovascular death among patients with incident DN. DN; diabetic 
nephropathy.
Model derivation, performance measure and validation
In the derivation dataset, the absolute risk of cardio-
vascular death within 2 years was 12.05%. Of the 27 
candidate predictors (online supplementary table 1), 
22 predictors (27 parameters) were statistically signifi-
cantly associated with cardiovascular death in the 
final multivariate model (table 2). Table 2 shows the 
apparent and internal validation performance statis-
tics of the risk prediction model. After adjustment for 
optimism, the final risk prediction model was able to 
discriminate patients with DN with and without cardio-
vascular death with a C- statistic of 0.736 (95% CI 0.731 
to 0.740). The agreement between the observed and 
predicted proportion of cardiovascular hospitalization 
and re- hospitalization showed good apparent calibra-
tion (figure 1, left). The optimism- adjusted calibration 
slope was 0.993 (95% CI 0.974 to 1.013) for cardiovas-
cular death (table 3).
external validation
In the external validation cohort, the absolute risks for 
cardiovascular death was 11.79%. Applying our final risk 
prediction model to the independent population gave a 
C- statistic of 0.747 (95% CI 0.737 to 0.756) for cardiovas-
cular death and good calibration (figure 1, right), with 
the calibration slope 1.000 (95% CI 0.981 to 1.020) for 
cardiovascular deaths.
A substantially underestimated cardiovascular risk was 
observed in the external validation cohort when applying 
the UKPDS risk score for 2- year risk both with (highest 
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Clinical examples
Figure 3 gives a clinical example of the application of 
prognostic score charts with graphical illustrations for 
the cardiovascular death prediction model to predict 
2- year risk of cardiovascular deaths.
disCussiOn
Main findings
A new risk prediction algorithm has been developed in 
this study to quantify the absolute risk of cardiovascular 
death within 2 years in a prospective cohort of Chinese 
patients with incident diagnosis of DN. The prediction 
model was then externally validated in another inde-
pendent prospective cohort. The risk prediction model 
demonstrated useful discrimination and excellent cali-
bration, with C- statistics of >0.70 both in the derivation 
cohort and external validation cohort. The risk predic-
tion model was derived from clinical measurements 
routinely recorded and accessible in diabetes care settings 
(outpatients and inpatients), indicating that these can be 
readily applied in routine diabetes care (eg, by embed-
ding in medical administrable software).
Comparison with previous studies
van der Sande et al developed a prediction model to 
predict cardiovascular events within 3 years among 
patients with prevalent DN treated with angiotensin 
receptor blockers.18 Age, gender, smoking, SBP, urinary 
albumin/creatinine ratio, eGFR, albumin and phos-
phate were included as predictors. However, the model 
performed poorly and yielded a C- statistic of 0.61 (95% 
CI 0.59 to 0.64) with a general slope calibration >1.00 (ie, 
the model overpredicted risk).
Previous risk prediction models have not fully 
addressed cardiovascular disease itself as the primary 
reason for death in patients with newly diagnosed DN. 
Being aware of the absolute risk of cardiovascular death 
in the following 2 years could help clinicians in their 
discussions with patients, and the urgency and intensity 
with which they provide cardiovascular event preventa-
tive care to patients with a high- risk profile, and could 
lead to a reduction in health cost overall. Implementa-
tion could be tested using a randomized controlled trial, 
with health economic assessment, and could include 
embedding alerts into practice software and increasing 
patient awareness of their risk.
Comparison with other risk score
The UKPDS risk score has been developed for patients 
who have newly diagnosed type 2 diabetes to estimate their 
1–10 years CVD risk. The algorithm performs well for the 
general population with type 2 diabetes.16 We applied 
the UKPDS risk score in the external validation cohort 
and found it substantially underestimated the 2- year CVD 
risk predicted. This might be due to levels of the UKPDS 
predictors (age, sex, glucose, SBP and lipid levels) being 
different in the population with DN compared with the 
wider type 2 diabetes population.3 This suggests that 
using the UKPDS risk engine to guide clinical manage-
ment might not be suitable among patients with type 2 
diabetes and DN. Our new risk score would be a more 
specific risk calculator for such patients.
strengths and limitations
There are several advantages in our prediction model 
over those applied elsewhere. The risk score is on the 
basis of absolute risk derivation and validation in two 
prospective cohorts. Demographic and clinical measure-
ments routinely recorded both in outpatient and inpa-
tient settings were used to derive the prediction model. 
This indicates that it can be readily embedded into 
online tools for their application in outpatient or inpa-
tient settings. Furthermore, compared with patients 
with type 2 diabetes, those with DN are on a fast- track to 
progress to a cardiovascular event, including premature 
cardiovascular death.1 3 The identification of individuals 
at high risk of cardiovascular deaths in the short term 
could help clinicians to prioritize new therapy (such as 
Sodium Glucose Co- Transporter-2 (SGLT-2) inhibitors) 
to delay a fatal (or non- fatal) cardiovascular event.
The approaches used to develop and validate the 
present model are similar to those for other risk predic-
tion models derived from the Clinical Practice Research 
Datalink (CPRD) and QResearch studies.19 20 The predic-
tors in our final model are accurate and reliable clinical 
variables routinely recorded in outpatient and inpatient 
settings and updated and reviewed for patients with 
DN having type 2 diabetes and are less varied than in 
other datasets. Moreover, the volume of missing values 
was relatively low, which would be less likely to lead to 
variation in potential external applications, although 
we applied multiple imputation. Caution is needed in 
interpreting the association between these predictors 
and the outcome, as the multiple imputation used might 
introduce information bias as the proportion of missing 
data was high with some predictors. This is likely to be 
less important as the aim of this study was to develop a 
risk score rather than investigating the causal associa-
tion between exposure (predictor) and the outcome: 
multiple imputation of predictors is a good approach for 
model derivation to improve prediction accuracy.21
In this study, the definition of an incident clinical 
diagnosis of DN was based on existing medical records. 
Naturally, the timing of the actual onset of DN would 
be unknown (as with many other non- communicable 
diseases), and the inclusion of prevalent cases would 
therefore be possible. However, renal function tests (ie, 
creatinine) were used routinely among patients with type 
2 diabetes to prospectively screen for chronic kidney 
disease and the possibility of enrolling prevalent cases 
was low. Restricted by current sample size and to facili-
tate utilization of the risk score, only polynomial terms 
of traditionally well- known prognostic factors (age, 
BMI, SBP, DBP, glucose, HbA1c, total cholesterol, LDL, 
HDL and triglycerides) were tested; polynomial terms 
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study. Further studies with large sample size and more 
polynomial terms of laboratory items are warranted. We 
acknowledge that antidiabetes treatments, diabetes dura-
tion, history of cardiovascular disease, antihypertensive 
treatment, lifestyle risk factors (like smoking) and other 
comorbidities were not taken into account as a result of 
limitations in the original data. However, some of these 
prognostic factors are very common in people with 
diabetes (such as antihypertensive treatment which is 
used in 81.2% of patients with type 2 diabetes22), and as 
a result, would be less discriminatory in the model. We 
also believe that at least some of the clinical measure-
ments incorporated in the prediction model could serve 
as proxies for these inaccessible predictors. Due to the 
sample size of the derivation and validation cohorts, 
further independent external validations (eg, external 
data from other low- income and middle- income coun-
tries) with large sample size are warranted. As the risk 
score was derived and externally validated in Chinese 
population with type 2 diabetes and incident DN, further 
validations in other ethnic groups are warranted. Multi-
collinearity could exist between predictors in this study. 
However, instead to quantifying a causal association, the 
goal of this study was to make a prediction that would be 
less likely to be influenced by multicollinearity.23
COnClusiOns
In conclusion, this is the first study to derive a prediction 
model to quantify the 2- year absolute risk of cardiovas-
cular death among patients with type 2 diabetes and newly 
diagnosed DN. Our risk algorithm has three useful impli-
cations for DN practice. First, the risk score can be used 
as a screening tool to identify patients with high proba-
bility of cardiovascular death. The risk score is based on 
readily accessible clinical information routinely recorded 
either in outpatient setting or inpatient setting and eval-
uated by diabetes management teams. It can be readily 
embedded into heath administration computer systems 
or developed into a mobile application for a handheld 
device for ease of use. Second, the risk prediction score 
could be applied to establish new treatment thresholds 
in diabetes clinical practice through consensus develop-
ment of guidelines. Third, this new risk score is a more 
specific risk calculator for DN compared with the UKPDS 
risk score.
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